[1] J-C Ameisen, C Burlet, M Canto-Sperber, P Cossart ,
CDeschamps, H Gaumont-Prat, A Grimfeld,
J-A Lepesant, M Loizeau, J-L
Lorrain,J Montagut,C de Rouffignac . (2007) Questions éthiques
posées par les nanosciences, les nanotechnologies et la santé
p19.
[2] D WIDED (2010) Nanoparticules d'or et d'argent
déposées sur oxyde de cérium synthétisées
sous
irradiation. Mémoire de magister en physique option rayonnenmnt
et applications Université MENTORI Canstantine Algérie p90.
[3] M Poúar (2010) Nanomedicine: a way of targeting and
detection of cancer cells Université de
Ljubljana p14.
[4] PERRIER. (2009)Modifications de nanocapsules lipidiques
par des procédés post-formulation.
Elaboration de vecteurs
multifonctionnels de médicaments. Thèse de doctorat
Spécialité : Neurosciences.Ecole Doctorale Nantes-Angers-Le Mans
p191.
[5] J Ogier(2008) Evaluation de Nanobagues comme Vecteurs de
Delivrance de Medicaments thèse de
doctorat Université de
Paris Sud U.F.R. Scientifique d'Orsay p261.
[6] E Blanco, C W. Kessinger, B D. Sumer, J Gao (2009)
Experimental Biology and Medicine--
Blanco.234:123-131.
[7] M HAYDER. (2011)Utilisation d'un Dendrimère
Phosphoré comme une Nouvelle Approche
Thérapeutique de la
Polyarthrite Rhumatoïde. Thèse de doctorat de l'université
de Toulouse p202.
[8] K RAHME. (2008) Stabilisation de nanoparticules dans
l'eau par des copolymères a blocs .Thèse
de doctorat de
l'université de Toulouse p246.
[9] Erik C. Dreaden, M A. El-Sayed, I H. El-Sayed.
Nanotechnology and Nanostructures Applied to
Head and Neck Cancer.
Nanomedicine and Cancer 20:373-395.
[10] J MERIAN(2012) Developpement et caracterisation in vivo
de nanoparticules lipidiques
biocompatibles au moyen des techniques
d'imagerie de fluorescence et nucleaire these de doctorat de
l'université Paris Descartes p297.
[11] F Alexis, E M. Pridgen, R Langer, OC. Farokhzad. (2010)
Nanoparticle Technologies for Cancer
Therapy .Drug Delivery, Handbook of
Experimental Pharmacology 197:55-86.
[12] V EL KHOURY(2006) étude de modifications
epigenetiques correlées à l'expression du gène
MDR1 et
à la texture nucleaire dans les cellules de carcinome pulmonaire H69
sensibles et résistantes à la chimiothérapie. thèse
de doctorat, université de Reims Champagne-Ardenne p253.
[13] D Peer, Jeffrey M. Karp,S Hong, O C. Farokhzad,R
Margalit, R Langer(2007) Nanocarriers as an
emerging platform forcancer
therapy nature nanotechnology 2 :751-760.
[14] C Ming, J Hu , L Zhang (2009)Therapeutic Nanoparticles
to Combat Cancer Drug Resistance
Current Drug Metabolism 10:836-841.
[15] A PAILLARD(2009) Franchissement de barrières
biologiques, mécanisme d'action et devenir
subcellulaire de
nanovecteurs d'agents anticancéreux pour la thérapie des gliomes.
Thèse de doctorat, université d'Angers p299.
[16] P Couvreur (2010) Les nanotechnologies peuvent-elles
contribuer à traiter des maladies sévères ?
Chaire
d'Innovation Technologique Liliane Bettencourt 2009-2010. P43.
[17] D Paolino, D Cosco, L Racanicchi, E Trapasso, C Celia ,M
Iannone, E Puxeddu, G Costante, S
Filetti,D Russo , M Fresta (2010)
Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®:
Biodistribution,pharmacokinetic features and in vivo antitumor activity.
Journal of Controlled Release 144: 144-150.
[18] C Hapca, L. Nobs , F. Buchegger, R. Gurny, F. Delie.
(2007) Differential tumor cell targeting of
anti-HER2 (Herceptin®)
andanti-CD20 (Mabthera®) coupled nanoparticles .International Journal of
Pharmaceutics 331:190-196.
[19] Z Zhanga, S H Leeb, S S Feng. (2007) Folate-decorated
poly (lactide-co-glycolide)-vitamin E
TPGSnanoparticles for targeted drug
delivery .Biomaterials 28:1889-1899.
[20] T A. Elbayoumi, V P. Torchilin. (2007) Enhanced
cytotoxicity of monoclonal anticancer
antibody2C5-modified
doxorubicin-loaded PEGylated liposomesagainst various tumor cell lines.european
journal of pharmaceutical sciences 3 2:159-168.
[21] J Pan, S S Feng. (2008) Targeted delivery of paclitaxel
using folate-decorated poly (lactide)
evitamin E TPGS nanoparticles
Biomaterials 29:2663-2672.
[22] J Ding , C Xiao , Y Li , Y Cheng , N Wang , C He ,X
Zhuang, X Zhu , X Chen . (2013) Efficacious
hepatoma-targeted nanomedicine
self-assembled from galactopeptide and doxorubicin driven by two-stage physical
interactions. Journal of Controlled Release xxx xxx-xxx.
[23] T. Dvir, M.R. Banghart, B.P. Timko, R. Langer, D.S. Kohane
(2010) Le ciblage de nanoparticules
par la lumière Nanoletters(1),
250.
[24] L. Raffaghello, G. Pagnan, F. Pastorino, E. Cosimo, C.
Brignole, D. Marimpietri,E. Bogenmann, M.
Ponzoni, P.G. Montaldo(2003) .
Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma
.Cancer Letters 197:151-155.
[25] Y Xiang, L Liang, X Wang, J Wang, X Zhang, Q Zhang.
(2011) Chloride channel-mediated brain
glioma targeting of
chlorotoxin-modifieddoxorubicine-loaded liposomes. Journal of Controlled
Release 152 402-410.
[26] H Chen, Y Qin, Q Zhang, W Jiang, L Tang, J Liu, Q He.
(2011) Lactoferrin modified doxorubicin-
loaded procationic liposomes for
the treatment of gliomas.European Journal of Pharmaceutical Sciences
44:164-173.
[27] L Zhang, S Zhu, L Qiana, Y Pei, Y Qiub, Y Jiang. (2011)
RGD-modified PEG-PAMAM-DOX
conjugates: In vitro and in vivo studies for
glioma .European Journal of Pharmaceutics and Biopharmaceutics 79:232-240.
[28] D Paolino, D Cosco, R Molinaro,C Celia, M Fresta.(
2011)Supramolecular devices to improve the
treatment of brain diseases .Drug
Discovery Today 16: 7/8 .
[29] S Wohlfarta, S Gelperinab, J Kreuter. (2012) Transport
of drugs across the blood-brain barrier by
nanoparticles. Journal of
Controlled Release 161:264-273.
[30] J Wang , Y Wang , W Liang. (2012) Delivery of drugs to
cell membranes by encapsulation in PEG-
PE micelles .Journal of Controlled
Release 160: 637-651.
[31] P. Couvreur , L. Roblot,Treupe F, M.F. Poupon , F.
Brasseur (1990) NANOPARTICLES AS
CARRIERS FOR ANTICANCER DRUGSAdvanced Drug
Delivery Reviews 5:209-230.
[32] Barraud L, Merle P, Soma E, Lefrançois L,
GuerretS,Chevallier M., DubernetC,Couvreur P., Trépo
C., Vitvitski
L.(2005). Increase of doxorubicin sensitivity by doxorubicin loading into
nanoparticles for hepatocellular carcinoma cells in vitro and in
vivo. J. Hepathology, 42: 736-743.
[33] J Liu , Y Zhao , Q Guoa, Z Wang , H Wang , Y Yang ,Y
Huang.(2012) TAT-modified nanosilver
for combating multidrug-resistant
cancer Biomaterials 33 :6155-6161.
[34] S Sengupta, D Eavarone, I Capila, G Zhao, N Watson, T
Kiziltepe,R Sasisekharan. (2005)Temporal
targeting of tumour cells and
neovasculature with a nanoscale delivery system .nature 436.
[35] R Duncan, M J. Vicent (2013) Polymer
therapeutics-prospects for 21st century: The end of the
beginning.Advanced
Drug Delivery Reviews 65:60-70.
[36] H C Kang, E S Lee, K Na, Y H Bae(2008) Stimuli-Sensitive
Nanosystems: For Drugand Gene
Delivery Multifunctional .Pharmaceutical
Nanocarriers 162-199.
[37] Y-H Jin , H-Y Hua, M-X Qiaoa, J Zhua, J-W Qia, C-J Hua,
Q Zhangb,D-W Chena(2012) pH-
sensitive chitosan-derived nanoparticles as
doxorubicin carriers for effective anti-tumor activity: preparation and in
vitro evaluation Colloids and Surfaces . Biointerfaces 94: 184- 191.
[38] S J Tabatabaei Rezaeia, M R Nabida, H Niknejadb, A A
Entezamic (2012)Folate-decorated
thermoresponsive micelles based on
star-shaped amphiphilicblock copolymers for efficient intracellular release of
anticancer drugs International Journal of Pharmaceutics 437 :70- 79.
[39] M-Y Huaa, H-W Yang , H-L Liu , R-Y Tsai , S-T Pang , K-L
Chuang ,Y-S Chang , T-L Hwang , Y-
H Chang , H-C Chuang , C-K Chuang
(2011)Superhigh-magnetization nanocarrier as a doxorubicin delivery platformfor
magnetic targeting therapy .Biomaterials 32 :8999-9010.
[40] J.L. Viota, A. Carazo , J.A. Munoz-Gameza, K. Rudzkab,
R. Gómez-Sotomayor b, A. Ruiz-
Extremeraa,c,J. Salmeróna,c,
A.V. Delgado , (2013) Functionalized magnetic nanoparticles as vehicles for the
delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in
vitro evaluation .Materials Science and Engineering C 33 :1183-1192.
[41] S Mura, P Couvreur. (2012) Nanotheranostics for
personalized medicine Advanced Drug Delivery
Reviews 64: 1394-1416.
[42] a/H Reddy L., Khoury H., Paci A., Deroussent A.,
Ferreira H., Dubernet C., Declèves X., Besnard
M., Chacun H.,
Lepêtre-Mouelhi S., Desmaële D.,Rousseau B., Laugier C.,
CintratJ.-C., Vassal G., Couvreur P.(2007). Squalenoylation favorably modifies
the in vivo pharmacokinetics and biodistribution of gemcitabinein mice.J.
Control. Rel. 124 :20-27.
b/Reddy L.H., Renoir J.M., Marsaud V., Lepêtre-Mouelhi
S.,Desmaële D., Couvreur P.(2009).Anticancer Efficacity of Squalenoyl
Gemcitabine Nanomedicine on 60 Human Tumor Cell Panel and on Experimental
Tumor. Molecular Pharmaceutics, 6 : 1526-1535.
[43] S Réjiba, L. Harivardhan Reddy,, C Bigand,C
Parmentier, P Couvreur, A Hajri, (2011) Squalenoyl
gemcitabine nanomedicine
overcomes the low efficacy of gemcitabine therapy in pancreatic cancer .nanomed
journal 7 :841-849.
[44]
www.cnrs.fr.
[45] Andrew Z. Wang, R Langer,Omid C. Farokhzad. (2012)
Nanoparticle Delivery of Cancer Drugs
Annu. Rev. Med. 63:185-98.
[46] R Wang, P S. Billone, W M. Mullett. (2013) Nanomedicine
in Action: An Overview of Cancer
Nanomedicine on the Market and in Clinical
Trials .Journal of Nanomaterials ID 629681, p 12.
[47]
www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
[48]
www.ema.europa.eu.
[49]
www.drugs.com.
[50] P Couvreur (2010) Les nanomedicaments .Innovation
technologique Liliane Bettencourt 927-942.
[51] R Duncan,R Gaspar . (2011)Nanomedicine under the
Microscope .Mol. Pharmaceutics XXXX,
XXX, 000-000.
[52] R.R. Bhagwat, I.S. Vaidhya. (2013) Novel drug delivery
systems: an overview Internatienal Journal
of Pharmaceutical Sciences and
Research, 4(3): 970-982.
[53] M Zhang (2013) Fungus-based nanoparticles: inspiration
from nature for cancer therapy.
Nanomedicine 8(3):313-316.
[54] R A. Freitas Jr. (2006) Pharmacytes: An Ideal Vehicle
for Targeted Drug Delivery. Journal of
Nanoscience and Nanotechnology 6:
2769-2775.
[55] P Couvreur (2010) Les nanomédicaments : une
approche intelligente pour le traitement des maladies
sévères
La chimie et la santé EDP Sciences, isbn : 978-2-7598-0488-7, p. 105.
[56] M Goutayer (2008) Nano-émulsions pour la
vectorisation d'agents thérapeutiques ou diagnostiques ;
étude
de la biodistribution par imagerie de fluorescence in vivo. Thèse de
doctorat de l'université Pierre et Marie Curie p241.
[57] P. Couvreur, 2009-2010.Nanomedicaments: materiaux et
methodes de preparation. Chaire
d'Innovation Technologique.
[58] E Fattal, H Hillaireau, S Mura, J Nicolas, N Tsapis
(2012)Targeted Delivery Using Biodegradable
Polymeric Nanoparticles Drug
Delivery, Advances in Delivery Science and Technology 10:255288.
[59] H Hillaireau, P Couvreur (2009) Nanocarriers' entry into
the cell: relevance to drug delivery
Cellular and Molecular Life
Sciences66:2873-2896.
